← FDA DRUG APPROVALS

FDA NDA · NDA021995

JANUVIA

sitagliptin

Sponsor: MSD

APPLICATION
NDA021995
TYPE
NDA
ORIGINAL APPROVAL
2006-10-16
LATEST ACTION
2023-12-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

JANUVIA · ReferencePrescription
SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET · ORAL
JANUVIA · ReferencePrescription
SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET · ORAL
JANUVIA · ReferencePrescription
SITAGLIPTIN PHOSPHATE EQ 25MG BASE · TABLET · ORAL

Approval history

2023-12-28Manufacturing (CMC) · Supplement 53LabelAP
2022-06-21Labeling · Supplement 50 · standardLetterAP
2020-12-04Efficacy · Supplement 47 · priorityLabelAP
2019-08-12Efficacy · Supplement 45 · standardLetterAP
2019-07-01Labeling · Supplement 46 · 901 requiredLetterAP
2018-02-09Labeling · Supplement 42 · standardLabelAP
2017-08-10Labeling · Supplement 40 · standardLabelAP
2017-01-18Labeling · Supplement 38 · standardLabelAP
2016-01-11Manufacturing (CMC) · Supplement 35 · standardAP
2015-08-28Labeling · Supplement 34 · 901 requiredLabelAP
2015-04-27Labeling · Supplement 33 · standardLabelAP
2015-03-10Manufacturing (CMC) · Supplement 32 · standardLetterAP
2013-10-17Manufacturing (CMC) · Supplement 28 · standardLabelAP
2013-08-19Labeling · Supplement 29 · standardLetterAP
2013-02-11Labeling · Supplement 27 · standardLabelAP
2012-12-07Manufacturing (CMC) · Supplement 26 · standardAP
2012-10-18Labeling · Supplement 25 · unknownLabelAP
2012-03-24Labeling · Supplement 23 · unknownLetterAP
2012-02-27Manufacturing (CMC) · Supplement 19LabelAP
2011-06-10Labeling · Supplement 16 · unknownLetterAP
2011-04-14Labeling · Supplement 17 · unknownLetterAP
2010-09-24Efficacy · Supplement 15 · standardLabelAP
2010-09-24Labeling · Supplement 18 · unknownLetterAP
2010-02-26Efficacy · Supplement 11 · standardLetterAP
2010-02-26Labeling · Supplement 14 · 901 requiredReviewAP
2010-02-26Efficacy · Supplement 12 · standardLabelAP
2010-02-26Efficacy · Supplement 10 · standardLabelAP
2009-12-28Labeling · Supplement 13 · 901 requiredLabelAP
2008-10-20Labeling · Supplement 9 · standardLetterAP
2008-07-22Labeling · Supplement 7 · standardLetterAP
2007-10-12Labeling · Supplement 6 · standardLetterAP
2007-10-12Labeling · Supplement 4 · standardLetterAP
2007-10-12Efficacy · Supplement 2 · unknownLetterAP
2007-10-12Efficacy · Supplement 3 · unknownLetterAP
2007-04-10Manufacturing (CMC) · Supplement 1AP
2006-10-16Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →